Cargando…

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism

PURPOSE: This study aimed to investigate the effect of Semaglutide on skeletal muscle and its metabolomics. METHODS: A total of 18 male C57BL/6 mice were randomly divided into normal control (NC) group, high-fat diet (HFD) group and HFD+Semaglutide group, and were given standard diet, HFD diet, HFD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Qingjuan, Chen, Shuchun, Chen, Xing, Niu, Shu, Yue, Lin, Pan, Xiaoyu, Li, Zelin, Chen, Xiaoyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594960/ https://www.ncbi.nlm.nih.gov/pubmed/36304787 http://dx.doi.org/10.2147/DDDT.S381546

Ejemplares similares

Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
por: Yue, Lin, et al.
Publicado: (2022)

Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
por: Chen, Xing, et al.
Publicado: (2022)

Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
por: Niu, Shu, et al.
Publicado: (2022)

Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2023)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
por: Alorfi, Nasser M, et al.
Publicado: (2022)

Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)

UTP14A, DKC1, DDX10, PinX1, and ESF1 Modulate Cardiac Angiogenesis Leading to Obesity-Induced Cardiac Injury
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Sarcopenia, Obesity, and Sarcopenic Obesity: Relationship with Skeletal Muscle Phenotypes and Single Nucleotide Polymorphisms
por: Khanal, Praval, et al.
Publicado: (2021)

Correlation of Obesity and Overweight with Cervical Vascular Function Among Healthy Populations
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
por: Masaki, Takayuki, et al.
Publicado: (2022)

Correlation between Cardiac Ultrasound Index and Cardiovascular Risk in Healthy Obese and Overweight Populations
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes”
Publicado: (2022)

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice
por: Zhu, Ruiyi, et al.
Publicado: (2023)

Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review)
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Sarcopenic osteoporosis, sarcopenic obesity, and sarcopenic osteoporotic obesity in the Camargo cohort (Cantabria, Spain)
por: Hernández-Martínez, Paula, et al.
Publicado: (2022)

Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control
por: Dantas, Wagner S., et al.
Publicado: (2022)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
por: Niu, Shu, et al.
Publicado: (2023)

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
por: Mahapatra, Manoj Kumar, et al.
Publicado: (2022)

Dynapenia, Muscle Quality, and Hepatic Steatosis in Patients with Obesity and Sarcopenic Obesity
por: Frigerio, Francesco, et al.
Publicado: (2023)

Sarcopenia and Sarcopenic Obesity
por: Choi, Kyung Mook
Publicado: (2013)

Sarcopenia and sarcopenic obesity
por: Choi, Kyung Mook
Publicado: (2016)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Effect of high-fat diet and empagliflozin on cardiac proteins in mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

Effects of low skeletal muscle mass and sarcopenic obesity on albuminuria: a 7-year longitudinal study
por: Yoo, Jee Hee, et al.
Publicado: (2020)

Sarcopenic obesity and cognitive performance
por: Tolea, Magdalena I, et al.
Publicado: (2018)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Effect of empagliflozin on cytoskeletal repair in the hippocampus of obese mice
por: Chen, Xiaoyi, et al.
Publicado: (2022)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
por: Kim, Hwi Seung, et al.
Publicado: (2021)

Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi‐continent study
por: Tyrovolas, Stefanos, et al.
Publicado: (2015)

Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy
por: Chen, Xing, et al.
Publicado: (2022)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Examining the Association Between Serum Leptin and Sarcopenic Obesity
por: Yang, Zhe-Yu, et al.
Publicado: (2021)

Sarcopenic Obesity and Endocrinal Adaptation with Age
por: Sakuma, Kunihiro, et al.
Publicado: (2013)

Prevention and Treatment of Sarcopenic Obesity in Women
por: Petroni, Maria L., et al.
Publicado: (2019)

Sarcopenic obesity: time to target the phenotypes
por: Perna, Simone, et al.
Publicado: (2019)

Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy
por: Vera, Kathryn, et al.
Publicado: (2020)

CONTROVERSIES AND CHALLENGES IN DEFINING SARCOPENIC OBESITY
por: Batsis, John A
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ggtqtinhtr8sh24jdsb8lfi4cc